Calcium blockers: antiatherogenic action by influencing the prostaglandin-system.
Weiss
K
K
Atherosclerosis Research Group, Vienna, Austria.
Fitscha
P
P
Gazsó
A
A
Gludovacz
D
D
Sinzinger
H
H
D000328:Adult; D000818:Animals; D001161:Arteriosclerosis / Q000517:prevention & control*; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D004110:Diltiazem / Q000494:pharmacology; D011464:Epoprostenol / Q000096:biosynthesis; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D017275:Isradipine; D008297:Male; D008315:Malondialdehyde / Q000097:blood; D009543:Nifedipine / Q000494:pharmacology; D010974:Platelet Aggregation / Q000187:drug effects; D011453:Prostaglandins / Q000502:physiology*; D011725:Pyridines / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D014700:Verapamil / Q000494:pharmacology
D002121:Calcium Channel Blockers; D011453:Prostaglandins; D011725:Pyridines; D008315:Malondialdehyde; D014700:Verapamil; D011464:Epoprostenol; D004110:Diltiazem; D009543:Nifedipine; D017275:Isradipine